Regeneron is just another victim of the outflows from healthcare, there is nothing positive to cling to on the chart. As earnings approaches price action can only indicate that more selling is imminent, short for now and look for long on test of support or trend line.
$REGN Regeneron Pharma - 50d/200d ema Golden Cross on the daily chart last week after a solid earnings report in early August. Assuming bullish trend line holds, expecting continued gains over the next couple months.
Near term target - $391 (gap fill)
Medium term target - $420
TEVA: Teva Pharmaceutical Industries Ltd.
Regeneron and Teva Announce Positive Topline Phase 3 Fasinumab Results in Patients with Chronic Pain from Osteoarthritis of the Knee or Hip